BP and favorable outcome (mRS 0–1 at 90 days).

<p>BP and favorable outcome (mRS 0–1 at 90 days).</p

BP grouping of different time points and SICH.

<p>BP grouping of different time points and SICH.</p

BP grouping of different time points & favorable outcome (mRS 0–1 at 90 days).

<p>BP grouping of different time points & favorable outcome (mRS 0–1 at 90 days).</p

Baseline characteristics and clinical outcome.

<p>Baseline characteristics and clinical outcome.</p

Validation of the mSOAR and SOAR scores to predict early mortality in Chinese acute stroke patients

<div><p>Background</p><p>It is unclear in Chinese patients with acute stroke how the SOAR (stroke subtype, Oxfordshire Community Stroke Project classification, age, and prestrike modified Rankin) and mSOAR (modified-SOAR) scores performed in predicting discharge mortality and 3-month mortality. We aimed to validate the predictability of these scores in this cohort.</p><p>Methods</p><p>Data from the China National Stroke Registry (CNSR) study was used to perform the mSOAR and SOAR scores for predicting the discharge and 3-month mortality in acute stroke patients.</p><p>Results</p><p>A total of 11073 acute stroke patients were included in present study. The increased mSOAR and SOAR scores were closely related to higher death risk in acute stroke patients. For discharge mortality, the area under the receiver-operator curve (AUC) of the mSOAR and SOAR scores were 0.784 (95% CI 0.761–0.807) and 0.722 (95% CI: 0.698–0.746). For 3-month mortality, they were 0.787 (95% CI: 0.771–0.803) and 0.704 (95% CI: 0.687–0.721), respectively. The mSOAR and SOAR scores showed significant correlation between the predicted and observed probabilities of discharge mortality (mSOAR: <i>r</i> = 0.945, <i>P</i> = 0.001; SOAR: <i>r</i> = 0.994, <i>P</i><0.001) and 3-month mortality (mSOAR: <i>r</i> = 0.984, <i>P</i><0.001; SOAR: <i>r</i> = 0.999; <i>P</i><0.001).</p><p>Conclusions</p><p>The mSOAR score predicted reliably the risk of death in Chinese acute stroke patients.</p></div

Validation of the mSOAR and SOAR scores to predict early mortality in Chinese acute stroke patients - Fig 1

<p>The discharge mortality and 3-month mortality were prognosticated by SOAR score (A) and mSOAR score (B). Patients with mSOAR score of 7 and 8 were merged into score of 6 for small sample size. Patients with SOAR score of 5 and 6 were merged into score of 4 for small sample size.</p

Validation of the mSOAR and SOAR scores to predict early mortality in Chinese acute stroke patients - Fig 3

<p>Calibration plot of (A) SOAR score for discharge mortality, (B) mSOAR score for discharge mortality, (C) SOAR score for 3-month mortality, and (D) mSOAR score for 3-month mortality. The vertical lines indicate the 95% confidence intervals of observed rates of mortality.</p

Characteristics of patients in included in the analysis (N = 11073).

<p>Characteristics of patients in included in the analysis (N = 11073).</p

Costs and Outcomes per Capita in Base-case Analysis.

<p>tPA, tissue plasminogen activator; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.</p><p>Costs and Outcomes per Capita in Base-case Analysis.</p

Outcomes and Efficacy of Patients Treated with tPA by Different Time From Onset to Needle.

<p>tPA, tissue plasminogen activator; mRS, modified Rankin Score; sICH, symptomatic intracerebral hemorrhage; ECASS II, Second European-Australasian Acute Stroke Study; TIMS-CHINA, Thrombolysis Implementation and Monitor of acute ischemic Stroke in China.</p><p>Outcomes and Efficacy of Patients Treated with tPA by Different Time From Onset to Needle.</p